title: Pressure mediates angiotensin II-induced arterial hypertrophy and PDGF-A expression.
abstract: Angiotensin II (Ang II) may induce arterial hypertrophy either directly or through an increase in arterial pressure. To separate these 2 mechanisms, rats were implanted with osmopumps delivering either Ang II (100 ng x kg-1 x min-1) or saline. 5-Bromo-2'-deoxyuridine (BrdU) was delivered to both groups by osmopump (2.5 microg x kg-1 x min-1). Half of the rats in each group were given minoxidil (9 mg x kg-1 . d-1) in their drinking water. After 14 days, systolic blood pressure was 117+/-2, 124+/-3, and 115+/-2 mm Hg in the control, Ang II-minoxidil, and minoxidil groups, respectively, and 181+/-6 mm Hg in the Ang II group (P<0.05). After perfusion-fixation, the thoracic aorta, carotid artery, small mesenteric artery, external spermatic artery, and kidneys were harvested, paraffin-embedded, and used for morphological measurements, immunohistochemistry for BrdU, and in situ hybridization with a 35S-labeled riboprobe for platelet-derived growth factor-A chain (PDGF-A) mRNA. The walls of the aorta and carotid arteries hypertrophied in the Ang II group only. There were no significant morphological differences in the small arteries. BrdU was negative in all arteries but positive in the renal tubules. Expression of PDGF-A was elevated 8-fold in the thoracic aorta of the Ang II group (P<0.05). These results show that (1) arterial hypertrophy from Ang II infusion occurs in response to elevated arterial pressure, (2) hypertrophy was not associated with hyperplasia or polyploidy of vascular smooth muscle cells, and (3) PDGF-A expression correlated with elevated pressure and arterial wall hypertrophy.
authors.affiliation: From the Department of Physiology, Eastern Virginia Medical School, Norfolk, VA 23501, USA.
authors.forename: S B
authors.initials: SB
authors.lastname: Parker
authors.forename: S S
authors.initials: SS
authors.lastname: Wade
authors.forename: R L
authors.initials: RL
authors.lastname: Prewitt
mesh_terms: D000704:Analysis of Variance; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000963:Antimetabolites / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D001973:Bromodeoxyuridine / Q000494:pharmacology*; D004347:Drug Interactions; D006984:Hypertrophy / Q000139:chemically induced / Q000517:prevention & control; D017403:In Situ Hybridization; D008297:Male; D008914:Minoxidil / Q000008:administration & dosage / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D000963:Antimetabolites; D010982:Platelet-Derived Growth Factor; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D008914:Minoxidil; D001973:Bromodeoxyuridine